Bluesight and Pfizer Global Hospital & Biosimilars have partnered to integrate SmartDose RFID-enabled medications with the KitCheck inventory management platform. This collaboration enables hospitals using KitCheck to procure SmartDose medications that are already tagged, encoded, and pre-associated at the point of manufacture. By moving the tagging process upstream, the partnership aims to reduce manual tagging labor for pharmacists and pharmacy technicians while improving inventory management efficiency and patient safety.

An estimated one-third of U.S. hospitals currently use RFID technology to enhance inventory management, strengthen regulatory compliance, and reduce medication waste. The initiative seeks to advance a standardized, interoperable approach that preserves the efficiency, safety, and visibility benefits of RFID. Bluesight’s engineers collaborated with Pfizer to ensure SmartDose adheres to industry best practices, including GS1 global data standards and ARC Spec S performance benchmarks.

Technical Specifications and Quality Assurance

Unlike hospital-based tagging programs, SmartDose applies RFID labels during manufacturing using proven GS1 encoding strategies and rigorous quality assurance processes. Each vial undergoes individual, automated readback verification before release to confirm the tag is readable and correctly encoded. These consistent manufacturing controls are designed to deliver a more reliable and accurate product while reducing the complexity of hospital-managed tagging programs.

Executive Commentary

“At Pfizer, we looked at the workflow hospitals were performing and asked a simple question: Why should pharmacists and pharmacy technicians be doing work that can be completed at the point of manufacture?” said Erin Pezant, Global Business Excellence Lead at Pfizer Global Hospital & Biosimilars. “SmartDose was designed to remove unnecessary manual steps from the pharmacy by delivering medications that arrive already tagged and associated.”

Kevin MacDonald, CEO and co-founder of Bluesight, emphasized the collaborative nature of the supply chain. “For more than a decade, we've believed RFID works best when every part of the supply chain plays a role. Pfizer shares that vision, and this collaboration demonstrates what's possible when manufacturing and hospital workflow expertise come together.”

Pfizer SmartDose medications are projected to be available for purchase in the second half of 2026.

Pfizer has temporarily discontinued Premarin Vaginal Cream in India due to supply challenges, with the company indicating that the financial impact of this decision is expected to be minimal. The company is currently exploring options to resume the supply of this product in the market as soon as possible.

Impact on Product Availability

The decision affects the availability of Premarin Vaginal Cream, a medication used in hormone replacement therapy. The key details surrounding this development are outlined below:

Company Response

Pfizer has not provided a specific timeline for when the supply will resume. The company is actively working to address the supply constraints and has stated that further updates regarding the resumption of supply are expected once the situation stabilizes.